Premium
Response to Jani et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
Author(s) -
Kane Barry
Publication year - 2017
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12748
Subject(s) - medicine , adalimumab , biosimilar , inclusion and exclusion criteria , randomized controlled trial , immunogenicity , drug , pharmacology , alternative medicine , immunology , antibody , disease , pathology